Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing potential first-in-class monoclonal and bispecific antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead program, SL-325, is a DR3 blocking antibody being developed for inflammatory bowel disease and other autoimmune conditions.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.